Introduction and Objective: Glycemic variability (GV) is associated with poor glycemic control and complications in patients with T2DM. The coefficient of variation (CV) derived from CGM has been widely used as a reliable measure of GV.Methods: A total of 773 patients with T2DM were included. A multivariate linear regression model was used to assess independent associations between CV and clinical factors, including age, sex, BMI, diabetes duration, HbA1c, use of antidiabetic medications, and estimated glomerular filtration rate (eGFR). A subgroup analysis of 396 patients with HbA1c <7.5% was also performed.Results: The mean age was 53.37±11.74 years, and 60.4% were male. Higher age was significantly associated with increased CV (β=0.08, p<0.001). Lower BMI (<18.5kg/m²) was significantly associated with higher CV compared to normal BMI (18.5-25 kg/m²) (β=4.40, p=0.006), while BMI 25-30 kg/m² was associated with lower CV (β=-0.94, p=0.046). Longer diabetes duration (≥10 years vs. <5 years) (β=3.24, p<0.001) and higher HbA1c (≥9.0% vs. <7.5%) (β = 1.44, p=0.010) were associated with increased CV. Use of oral combination therapy with three agents (β=2.31, p=0.010), GLP-1 RAs (β=2.14, p=0.005), and insulin (β=4.63, p<0.001) were also associated with higher CV. Additionally, in the subgroup analysis of patients with HbA1c <7.5%, similar patterns of association were observed; higher age, lower BMI (<18.5 kg/m²), use of triple oral agents, GLP-1 RAs, and insulin were significantly associated with higher CV.Conclusion: Higher age, lower BMI, longer diabetes duration, higher HbA1c, and use of triple oral therapy, GLP-1 RAs, and insulin were associated with greater GV in patients with T2DM. Our study suggests that GV management strategies should consider these clinical factors to improve glycemic stability.
S. Jang: None. S. Kwon: None. W. Hong: None. C. Kim: None. S. Park: None. K. Kim: None.
Source link
Leave a Reply